Amlitelimab Data in Eczema Indicate Potential for Disease Modification
Summary
AAD roundtable panel weighs phase III efficacy, itch response, and safety
Description
AAD roundtable panel weighs phase III efficacy, itch response, and safety
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source